JP2019536805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536805A5 JP2019536805A5 JP2019530011A JP2019530011A JP2019536805A5 JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5 JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019530011 A JP2019530011 A JP 2019530011A JP 2019536805 A5 JP2019536805 A5 JP 2019536805A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- administered
- cdk4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 68
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims 26
- 239000002246 antineoplastic agent Substances 0.000 claims 26
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 25
- 229960004562 carboplatin Drugs 0.000 claims 25
- 229960005420 etoposide Drugs 0.000 claims 24
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 24
- 229940127089 cytotoxic agent Drugs 0.000 claims 23
- 206010006187 Breast cancer Diseases 0.000 claims 12
- 208000026310 Breast neoplasm Diseases 0.000 claims 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 12
- 229960003852 atezolizumab Drugs 0.000 claims 12
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims 12
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 11
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 11
- 239000012271 PD-L1 inhibitor Substances 0.000 claims 11
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 11
- 238000011282 treatment Methods 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 238000012423 maintenance Methods 0.000 claims 9
- 206010041067 Small cell lung cancer Diseases 0.000 claims 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 6
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 230000006698 induction Effects 0.000 claims 6
- 229960001592 paclitaxel Drugs 0.000 claims 6
- 229940121655 pd-1 inhibitor Drugs 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 6
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims 4
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 4
- 229960004316 cisplatin Drugs 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 229940044683 chemotherapy drug Drugs 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960002949 fluorouracil Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
- 229960001756 oxaliplatin Drugs 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 102000015694 estrogen receptors Human genes 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022091214A JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430302P | 2016-12-05 | 2016-12-05 | |
| US62/430,302 | 2016-12-05 | ||
| US201762479605P | 2017-03-31 | 2017-03-31 | |
| US62/479,605 | 2017-03-31 | ||
| PCT/US2017/064775 WO2018106729A1 (en) | 2016-12-05 | 2017-12-05 | Preservation of immune response during chemotherapy regimens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Division JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536805A JP2019536805A (ja) | 2019-12-19 |
| JP2019536805A5 true JP2019536805A5 (enExample) | 2021-01-21 |
Family
ID=62491342
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530011A Pending JP2019536805A (ja) | 2016-12-05 | 2017-12-05 | 化学療法計画中の免疫応答の保護 |
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091214A Active JP7483791B2 (ja) | 2016-12-05 | 2022-06-03 | 化学療法計画中の免疫応答の保護 |
| JP2023143202A Active JP7710496B2 (ja) | 2016-12-05 | 2023-09-04 | 化学療法計画中の免疫応答の保護 |
| JP2025115144A Pending JP2025148426A (ja) | 2016-12-05 | 2025-07-08 | 化学療法計画中の免疫応答の保護 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11529352B2 (enExample) |
| EP (1) | EP3548030A4 (enExample) |
| JP (4) | JP2019536805A (enExample) |
| KR (4) | KR20190092478A (enExample) |
| CN (3) | CN110035759A (enExample) |
| AU (4) | AU2017372856B9 (enExample) |
| BR (1) | BR112019011410A2 (enExample) |
| CA (1) | CA3045465A1 (enExample) |
| IL (4) | IL317919A (enExample) |
| MX (2) | MX2019006523A (enExample) |
| NZ (2) | NZ753631A (enExample) |
| WO (1) | WO2018106729A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527857B2 (en) * | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2015166986A1 (ja) | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| MX2019006523A (es) | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| TWI823845B (zh) | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| SMT202500440T1 (it) | 2017-03-31 | 2026-01-12 | Fujifilm Corp | Composizione liposomiale e composizione farmaceutica |
| WO2019054865A1 (en) * | 2017-09-14 | 2019-03-21 | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) | T-cell based immunotherapy |
| US20200377599A1 (en) * | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| JP7364561B2 (ja) * | 2018-06-20 | 2023-10-18 | 富士フイルム株式会社 | ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| WO2019244979A1 (ja) * | 2018-06-20 | 2019-12-26 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| EP3853251A1 (en) * | 2018-09-19 | 2021-07-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
| TWI837189B (zh) | 2018-10-01 | 2024-04-01 | 日商富士軟片股份有限公司 | 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥 |
| CN113271977A (zh) * | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| US20220288067A1 (en) * | 2019-04-24 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Treatment of cancer with cdk inhibitors |
| TWI879768B (zh) * | 2019-05-03 | 2025-04-11 | 美商建南德克公司 | 用抗pd-l1抗體治療癌症之方法 |
| EP3986410A4 (en) * | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| EP4058824A4 (en) | 2019-11-12 | 2022-12-28 | Pointcloud Inc. | TWO-WAY LIGHT DETECTION AND DISTANCE MEASUREMENT SYSTEM |
| WO2021110122A1 (zh) * | 2019-12-05 | 2021-06-10 | 基石药业（苏州）有限公司 | Cdk4/6抑制剂的组合疗法 |
| EP4652997A3 (en) | 2020-05-19 | 2026-03-04 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TWI906312B (zh) * | 2020-06-15 | 2025-12-01 | 大陸商海南先聲再明醫藥股份有限公司 | 曲拉西利(trilaciclib)之型態形式及製造方法 |
| WO2022087018A1 (en) * | 2020-10-19 | 2022-04-28 | G1 Therapeutics, Inc. | Improved fluorouracil-based multi-agent chemotherapy for treatment of metastatic colorectal cancer |
| EP4255576A4 (en) * | 2020-12-07 | 2024-10-23 | The Trustees of Indiana University | METHODS FOR SENSITIZING CANCER CELLS TO IMMUNE ATTACK USING ATRACTYLENOLIDE I |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| WO2023068220A1 (ja) * | 2021-10-18 | 2023-04-27 | 株式会社Preferred Networks | 予測方法及びバイオマーカー |
| EP4482522A4 (en) * | 2022-02-25 | 2026-03-18 | Lanier Biotherapeutics Inc | ANTI-ALARMIN BINDING MOLECULES AND TREATMENT OF PNEUMONITIS |
| WO2024050145A1 (en) * | 2022-09-02 | 2024-03-07 | Rs Oncology, Llc | Thiostrepton dosing regimens |
| WO2024216208A2 (en) * | 2023-04-14 | 2024-10-17 | Concarlo Therapeutics, Inc. | Brk peptides and methods of use |
| EP4713680A2 (en) * | 2023-05-15 | 2026-03-25 | Cedars-Sinai Medical Center | Y chromosome gene signature as a target for cancer therapy in combination with immunotherapy |
| CN117511855B (zh) * | 2023-11-09 | 2024-11-19 | 南京医科大学 | Epha抑制剂在诱导减数分裂中的应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| WO2007124252A2 (en) | 2006-04-05 | 2007-11-01 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| KR101353857B1 (ko) | 2008-08-22 | 2014-01-21 | 노파르티스 아게 | Ｃｄｋ 억제제로서 피롤로피리미딘 화합물 |
| JP2012504646A (ja) | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護 |
| CN102231983A (zh) | 2008-10-01 | 2011-11-02 | 北卡罗来纳大学查珀尔希尔分校 | 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护 |
| CA2761896A1 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| MX379532B (es) | 2010-10-25 | 2025-03-10 | G1 Therapeutics Inc | Inhibidores de cdk. |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| MY161237A (en) | 2011-07-01 | 2017-04-14 | Novartis Ag | Combination therapy comprising a cdk4/6 inhibitor and a p13k inhibitor for use in the treatment of cancer |
| WO2013148748A1 (en) | 2012-03-29 | 2013-10-03 | Francis Xavier Tavares | Lactam kinase inhibitors |
| MY175254A (en) | 2012-04-26 | 2020-06-17 | G1 Therapeutics Inc | Synthesis of lactams |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| US20140271460A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Highly Active Anti-Neoplastic and Anti-Proliferative Agents |
| US9527857B2 (en) | 2013-03-15 | 2016-12-27 | GI Therapeutics, Inc. | HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2014168975A1 (en) | 2013-04-08 | 2014-10-16 | Pharmacyclics, Inc. | Ibrutinib combination therapy |
| CN105682683A (zh) * | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| JP2017513818A (ja) * | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
| WO2015161283A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| JP2017515859A (ja) | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| JP2018500332A (ja) * | 2014-12-16 | 2018-01-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 中枢神経系新生物における免疫チェックポイント阻害剤の使用 |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| CN109661228A (zh) | 2016-06-20 | 2019-04-19 | 库拉肿瘤学公司 | 用erk抑制剂治疗鳞状细胞癌 |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| EA201990187A1 (ru) | 2016-07-01 | 2019-07-31 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| CN109789142B (zh) | 2016-07-01 | 2022-08-23 | G1治疗公司 | N-(杂芳基)-吡咯并[3,2-d]嘧啶-2-胺的合成 |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| EP3538148A1 (en) | 2016-11-08 | 2019-09-18 | Dana-Farber Cancer Institute | Compositions and methods of modulating anti-tumor immunity |
| US20190275049A1 (en) | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
| AU2017368286B2 (en) | 2016-11-30 | 2021-12-16 | Medizinische Universität Innsbruck | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors |
| MX2019006523A (es) | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| TWI823845B (zh) | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| US20200108066A1 (en) | 2017-03-30 | 2020-04-09 | Shorn Goel | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
| EP4455146A3 (en) | 2017-06-29 | 2025-01-01 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| US20200377599A1 (en) | 2017-11-30 | 2020-12-03 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| WO2019136244A1 (en) | 2018-01-04 | 2019-07-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CN112218634A (zh) | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| CN120817904A (zh) | 2018-08-24 | 2025-10-21 | 法码科思莫斯有限公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
| CN113271977A (zh) | 2018-11-09 | 2021-08-17 | G1治疗公司 | 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案 |
| EP3986410A4 (en) | 2019-06-18 | 2023-06-28 | G1 Therapeutics, Inc. | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128173A (zh) | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| IL309489A (en) | 2021-07-01 | 2024-02-01 | G1 Therapeutics Inc | Combined treatments in patients with cancer with advanced and/or metastatic TROP-2 overexpression |
-
2017
- 2017-12-05 MX MX2019006523A patent/MX2019006523A/es unknown
- 2017-12-05 JP JP2019530011A patent/JP2019536805A/ja active Pending
- 2017-12-05 CN CN201780075215.1A patent/CN110035759A/zh active Pending
- 2017-12-05 IL IL317919A patent/IL317919A/en unknown
- 2017-12-05 NZ NZ753631A patent/NZ753631A/en unknown
- 2017-12-05 BR BR112019011410-6A patent/BR112019011410A2/pt not_active Application Discontinuation
- 2017-12-05 KR KR1020197019110A patent/KR20190092478A/ko not_active Ceased
- 2017-12-05 WO PCT/US2017/064775 patent/WO2018106729A1/en not_active Ceased
- 2017-12-05 KR KR1020247004112A patent/KR20240024296A/ko active Pending
- 2017-12-05 AU AU2017372856A patent/AU2017372856B9/en active Active
- 2017-12-05 CA CA3045465A patent/CA3045465A1/en active Pending
- 2017-12-05 EP EP17878506.9A patent/EP3548030A4/en active Pending
- 2017-12-05 CN CN202311165820.1A patent/CN117562905A/zh active Pending
- 2017-12-05 CN CN202311165935.0A patent/CN117530948A/zh active Pending
- 2017-12-05 IL IL303038A patent/IL303038B2/en unknown
- 2017-12-05 NZ NZ795224A patent/NZ795224A/en unknown
- 2017-12-05 IL IL311265A patent/IL311265A/en unknown
- 2017-12-05 KR KR1020247004113A patent/KR20240023677A/ko not_active Withdrawn
- 2017-12-05 KR KR1020247004108A patent/KR20240023676A/ko active Pending
-
2019
- 2019-05-26 IL IL266870A patent/IL266870A/en unknown
- 2019-06-04 MX MX2023006991A patent/MX2023006991A/es unknown
- 2019-06-05 US US16/432,244 patent/US11529352B2/en active Active
-
2022
- 2022-06-03 JP JP2022091214A patent/JP7483791B2/ja active Active
- 2022-12-01 US US18/072,963 patent/US12527798B2/en active Active
-
2023
- 2023-09-04 JP JP2023143202A patent/JP7710496B2/ja active Active
- 2023-12-11 AU AU2023282170A patent/AU2023282170B2/en active Active
- 2023-12-11 AU AU2023282168A patent/AU2023282168B2/en active Active
-
2025
- 2025-07-08 JP JP2025115144A patent/JP2025148426A/ja active Pending
- 2025-10-01 AU AU2025242155A patent/AU2025242155A1/en active Pending